×
About 805 results

ALLMedicine™ Progeria Center

Research & Reviews  303 results

Progeria: a perspective on potential drug targets and treatment strategies.
https://doi.org/10.1080/14728222.2022.2078699
Expert Opinion on Therapeutic Targets; Benedicto I, Chen X et. al.

May 17th, 2022 - Progeria: a perspective on potential drug targets and treatment strategies.|2022|Benedicto I,Chen X,Bergo MO,Andrés V,|

Severe aortic stenosis during leptin replacement therapy in a patient with generalized ...
https://doi.org/10.1111/jdi.13827
Journal of Diabetes Investigation; Sasako T, Kadowaki H et. al.

May 8th, 2022 - Leptin replacement therapy (LRT) has drastically improved the prognosis of patients with lipodystrophy, but pro-inflammatory properties of leptin could become evident in the long run. Here we report a 30-year-old Japanese woman with generalized li...

Successful surgical aortic valve replacement in a patient with progeria.
https://doi.org/10.1093/icvts/ivac115
Interactive Cardiovascular and Thoracic Surgery; Vukovic P, Milacic P et. al.

May 7th, 2022 - The progeroid syndrome includes a group of rare, severe genetic disorders clinically characterized by premature physical ageing. Severe aortic stenosis has been described in progeria patients, but no previous surgical aortic valve replacement was ...

Aging-Conferred SIRT7 Decline Inhibits Rosacea-Like Skin Inflammation by Modulating Tol...
https://doi.org/10.1016/j.jid.2022.03.026
The Journal of Investigative Dermatology; Li G, Tang X et. al.

Apr 13th, 2022 - Rosacea is a chronic inflammatory skin disorder that manifests abnormal enhanced sensitivity to environmental stimuli. The decreased prevalence of rosacea in aged population has been reported, but the underlying mechanism is unclear. In this study...

Inhibition of activin A receptor signalling attenuates age-related pathological cardiac...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9118092
Disease Models & Mechanisms; Clavere NG, Alqallaf A et. al.

Apr 6th, 2022 - In the heart, ageing is associated with DNA damage, oxidative stress, fibrosis and activation of the activin signalling pathway, leading to cardiac dysfunction. The cardiac effects of activin signalling blockade in progeria are unknown. This study...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  3 results

Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
https://clinicaltrials.gov/ct2/show/NCT05229991

Feb 8th, 2022 - Background: Hepatitis D virus (HDV) was identified as the infectious agent causing viral hepatitis in the presence of hepatitis B virus (HBV). While HDV can replicate autonomously inside the hepatocyte, the virus requires co-infection with HBV to ...

Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
https://clinicaltrials.gov/ct2/show/NCT02579044

Jun 14th, 2021 - This is a phase I/II dose-escalation trial of everolimus in combination with lonafarnib in Hutchinson-Gilford Progeria Syndrome (HGPS) and progeroid laminopathies (henceforth "progeria"). The study will be conducted at a single clinical site utili...

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
https://clinicaltrials.gov/ct2/show/NCT00879034

Jun 13th, 2019 - Progerias are rare "premature aging" diseases in which children die of severe atherosclerosis leading to strokes and heart attacks. It is a multisystem disease with objective clinical markers for disease progression. These include abnormalities in...

see more →

News  14 results

FDA Approvals, Highlights, and Summaries: Pediatrics
https://reference.medscape.com/viewarticle/945192

Feb 24th, 2021 - Pediatric Endocrinology Zokinvy (lonafarnib) Lonafarnib, an oral farnesyltransferase inhibitor, is indicated to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome (HGPS). It was also approved for processing-deficient progeroid la...

FDA Approvals, Highlights, and Summaries: Endocrinology
https://reference.medscape.com/viewarticle/945183

Feb 24th, 2021 - Zokinvy (lonafarnib) Lonafarnib, an oral farnesyltransferase inhibitor, is indicated to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome (HGPS). It was also approved for processing-deficient progeroid laminopathies with heteroz...

Prehospital Cardiac Arrest Tx; Prior Authorization Findings; Progeria Tx
https://www.medpagetoday.com/cardiology/prevention/72570

Apr 27th, 2018 - Advanced life support on the way to the hospital for people in cardiac arrest from blunt trauma in a traffic accident has better outcomes than basic life support, especially when done by a physician, a Japanese national registry study reported. (J...

Progeria Often Comes with Silent LV Dysfunction
https://www.medpagetoday.com/cardiology/chf/71312

Feb 22nd, 2018 - The early cardiovascular death typical of Hutchinson-Gilford progeria syndrome may hide a surprising level of asymptomatic left ventricular (LV) diastolic dysfunction, researchers found. In a single-center series of 27 consecutive patients, ages 2...

FDA Approves First Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies
http://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-hutchinson-gilford-progeria-syndrome-and-some-progeroid-laminopathies

For Immediate Release: November 20, 2020 Today, the U.S. Food and Drug Administration approved Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of certain processing-defici...

see more →

Patient Education  1 results see all →